A Comparative Analysis of SARS-CoV-2 Antivirals Characterizes 3CL pro Inhibitor PF-00835231 as a Potential New Treatment for COVID-19 | Zendy

Maren de Vries | Zendy; Adil Mohamed | Zendy; Rachel A. Prescott | Zendy; Ana M. Valero-Jimenez | Zendy; Ludovic Desvignes | Zendy; Rebecca E. O’Connor | Zendy; Claire M. Steppan | Zendy; Joseph C. Devlin | Zendy; Ellie Ivanova | Zendy; Alberto Herrera | Zendy; Austin R. Schinlever | Zendy; Paige Loose | Zendy; Kelly V. Ruggles | Zendy; Sergei B. Koralov | Zendy; Annaliesa S. Anderson | Zendy; Joseph Binder | Zendy; Meike Dittmann | Zendy

Open Access

A Comparative Analysis of SARS-CoV-2 Antivirals Characterizes 3CL ^pro Inhibitor PF-00835231 as a Potential New Treatment for COVID-19

Author(s) -

Maren de Vries,

Adil Mohamed,

Rachel A. Prescott,

Ana M. Valero-Jimenez,

Ludovic Desvignes,

Rebecca E. O’Connor,

Claire M. Steppan,

Joseph C. Devlin,

Ellie Ivanova,

Alberto Herrera,

Austin R. Schinlever,

Paige Loose,

Kelly V. Ruggles,

Sergei B. Koralov,

Annaliesa S. Anderson,

Joseph Binder,

Meike Dittmann

Publication year - 2021

Publication title -

journal of virology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.617

H-Index - 292

eISSN - 1070-6321

pISSN - 0022-538X

DOI - 10.1128/jvi.01819-20

Subject(s) - a549 cell , vero cell , biology , protease inhibitor (pharmacology) , virology , coronavirus , viral life cycle , antiviral drug , lopinavir , cell culture , viral entry , respiratory epithelium , pharmacology , viral replication , in vitro , virus , respiratory system , viral load , covid-19 , medicine , biochemistry , disease , antiretroviral therapy , infectious disease (medical specialty) , genetics , pathology , anatomy

The arsenal of SARS-CoV-2 specific antiviral drugs is extremely limited. Only one direct-acting antiviral drug is currently approved, the viral polymerase inhibitor remdesivir, and it has limited efficacy.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research